SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2023
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant’s name into English)
75/76 Wimpole Street
London W1G 9RT
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
On May 1, 2023, Dr. Torsten Hombeck, Chief Financial Officer of Akari Therapeutics, Plc (the “Company”), delivered his notice of resignation. Dr. Hombeck’s resignation is not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. The Company and Dr. Hombeck have not yet determined the effective date of Dr. Hombeck’s resignation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Akari Therapeutics, Plc|
|By:||/s/ Rachelle Jacques|
President and Chief Executive Officer
Date: May 5, 2023